Roivant Sciences Ltd. ROIV 深 沪
等待开盘 08-10 09:30:00 美东时间
36.34
+1.220
+3.47%
华盛通- 最 高36.44
- 今 开35.88
- 成交量 663.43万股
- 最 低 33.11
- 昨 收 35.12
- 总市值 2514.73万
- 52周最高 37.00
- 市盈率 静 --
- 换手率 958.71%
- 52周最低 11.54
- 委 比 -87.66%
- 总股本 0.01亿
- 历史最高 37.00
- 量 比 1.28
- 振 幅 9.48%
- 历史最低 1.10
- 每 手 1
- 风险率 6.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study
HC Wainwright sees over $1 billion in sales potential for Argenx's Vyvgart in IMNM despite myositis trial changes.
06-26 01:57
Crude Oil Down 5%; Lowe's Posts Upbeat Earnings
US stocks rise with Dow gaining 1% on Wednesday. The Nasdaq and S&P 500 also saw gains. Lowe's Companies reported upbeat earnings.
05-21 00:16
Europe Clears First Flu/COVID Combo Shot From Moderna
Moderna stock rises after EU approval of flu-COVID combo vaccine mCOMBRIAX, backed by Phase 3 data showing strong immune response.
04-22 01:58
Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars
Moderna shares jump after a $950 million settlement over COVID-19 vaccine patents, easing investor concerns and clearing legal uncertainty.
03-04 21:14
Roivant Approves $1B Share Buyback Program
The buyback program is inclusive of the $500M authorization that was approved in June 2025
03-04 05:19
Roivant Signals Major Pipeline Momentum With Accelerated Timelines
Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.
2025-12-12 02:39
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
2025-11-10 19:12
Earnings Preview For Roivant Sciences
Roivant Sciences (NASDAQ:ROIV) will release its quarterly earnings report on Mo...
2025-11-07 22:01
470亿港元合作：晶泰控股与哈佛教授Verdine创AI制药史上合作订单新纪录
2025年8月5日，晶泰控股（02228.HK）宣布与哈佛大学教授Gregory Verdine创立的DoveTree正式签署最终协议，合作总规模达470亿港元...
2025-08-07 11:50
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
Roivant and Priovant Therapeutics announce a live investor video conference on June 17 to discuss brepocitinib's potential in addressing unmet medical needs for dermatomyositis patients. Brepocitinib, a TYK2/JAK1 inhibitor, is in Phase 3 trials for dermatomyositis and non-infectious uveitis, and Phase 2 for cutaneous sarcoidosis. The event will provide insights into its development and patient benefits.
2025-06-09 20:05
